151105-84-9

Upstream product

• 151105-85-0 1-(4-fluorophenyl)-5-methyl-2-(4-pyridyl)-1,4-hexanedione 
• 151105-87-2 1-(4-fluorophenyl)-5-methyl-2-(N-oxo-4-pyridyl)-1,4-hexanedione 

Downstream Products

• 151105-94-1 (E)-3-<2,3-bis(4-fluorophenyl)-5-(1-methylethyl)-1H-pyrrol-1-yl>-2-propenal 
• 151105-95-2 (Z)-3-<2,3-bis(4-fluorophenyl)-5-(1-methylethyl)-1H-pyrrol-1-yl>-2-propenal 
• 151105-96-3 (+/-)-(E)-7-<2,3-bis(4-fluorophenyl)-5-(1-methylethyl)-1H-pyrrol-1-yl>-5-hydroxy-3-oxo-6-heptenoic acid methyl ester 
• 151106-00-2 (E)-7-[2-(4-Fluoro-phenyl)-5-isopropyl-3-pyridin-4-yl-pyrrol-1-yl]-5-hydroxy-3-oxo-hept-6-enoic acid methyl ester 

Relevant academic research and scientific papers

Inhibitors of cholesterol biosynthesis. 2. 3,5-dihydroxy-7-(N-pyrrolyl)- 6-heptenoates, a novel series of HMG-CoA reductase inhibitors

A series of 7-[2,3-diaryl-5-(1-methylethyl)-1H-pyrrol-1-yl]-3,5-dihydroxy- 6-heptenoates was prepared and evaluated for its ability to inhibit the enzyme HMG-CoA reductase in vitro. Maintaining a 5-(1-methylethyl) substituent found to be optimal in related studies, structure-activity relationships were established for compounds modified at positions 2, 3, and 4 of the pyrrole ring. The 4-fluorophenyl group was preferred at the pyrrole 2-position, while incorporation of a range of substituted phenyl groups and pyridyl substituents at the 3-position provided compounds with equivalent enzyme inhibitory activities and widely different lipophilicities. Pentasubstituted pyrrole 3h was found to have a 10-fold greater potency than lovastatin.